Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 6.5%

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report)'s stock price rose 6.5% on Friday . The company traded as high as 1.68 and last traded at 1.63. Approximately 931,515 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 4,184,581 shares. The stock had previously closed at 1.53.

Analysts Set New Price Targets

CATX has been the subject of several research reports. Oppenheimer reaffirmed an "outperform" rating and set a $1.50 target price (up previously from $1.20) on shares of Perspective Therapeutics in a research note on Monday, April 1st. Royal Bank of Canada started coverage on shares of Perspective Therapeutics in a research note on Tuesday. They issued an "outperform" rating and a $3.00 price objective on the stock. B. Riley increased their target price on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the company a "buy" rating in a research note on Tuesday, April 9th. Cantor Fitzgerald initiated coverage on shares of Perspective Therapeutics in a report on Thursday, May 9th. They set an "overweight" rating for the company. Finally, Lifesci Capital reaffirmed an "outperform" rating on shares of Perspective Therapeutics in a report on Monday, May 6th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of 1.90.

Perspective Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 1.07 and a quick ratio of 1.07.

Insider Transactions at Perspective Therapeutics

In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the company's stock in a transaction dated Wednesday, March 6th. The shares were bought at an average price of 0.95 per share, with a total value of 57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares in the company, valued at approximately 110,934,724.30. The purchase was disclosed in a filing with the SEC, which is available through this link. 3.52% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Perspective Therapeutics

Several hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC acquired a new stake in Perspective Therapeutics during the first quarter worth about $15,511,000. Affinity Asset Advisors LLC bought a new stake in shares of Perspective Therapeutics during the first quarter valued at approximately $6,069,000. Vanguard Group Inc. increased its position in shares of Perspective Therapeutics by 34.6% during the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company's stock valued at $21,158,000 after purchasing an additional 4,566,356 shares during the period. Bleakley Financial Group LLC acquired a new position in shares of Perspective Therapeutics in the first quarter valued at $40,000. Finally, RIA Advisory Group LLC lifted its position in Perspective Therapeutics by 1,313.4% in the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company's stock worth $127,000 after purchasing an additional 99,293 shares during the period. 54.66% of the stock is owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.